

Tara L Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2510782/publications.pdf>

Version: 2024-02-01

113
papers

3,906
citations

279487

23
h-index

133063

59
g-index

114
all docs

114
docs citations

114
times ranked

6058
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional characterization of NPM1-TYK2 fusion oncogene. <i>Npj Precision Oncology</i> , 2022, 6, 3.	2.3	2
2	Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1708-1713.	0.6	6
3	Acute promyelocytic leukemia: A single institution's experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19001-e19001.	0.8	1
4	Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of foscicopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7069-TPS7069.	0.8	0
5	V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7043-7043.	0.8	1
6	Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7031-7031.	0.8	1
7	Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6542-6542.	0.8	0
8	A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia age 60 years: Phase 1b interim results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7027-7027.	0.8	2
9	High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 99-109.	0.7	7
10	Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. <i>Molecular Cancer Research</i> , 2021, 19, 913-920.	1.5	5
11	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , 2021, 5, 1719-1728.	2.5	13
12	Abstract P13: Prospective voluntary SARS-CoV-2 virus and anti-COVID-19 antibody tests in asymptomatic medical and research staff who work in direct contact with cancer patients: A single center study. , 2021, , .		0
13	The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 303-314.	1.0	4
14	Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7026-7026.	0.8	0
15	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e481-e491.	2.2	92
16	Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 110.	6.9	6
17	A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Cancers</i> , 2021, 13, 4113.	1.7	20
18	A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 175.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review. <i>Blood</i> , 2021, 138, 4389-4389.	0.6	0
20	Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results. <i>Blood</i> , 2021, 138, 2316-2316.	0.6	0
21	Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial. <i>Blood</i> , 2021, 138, 1268-1268.	0.6	2
22	Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. <i>Frontiers in Oncology</i> , 2021, 11, 806243.	1.3	1
23	A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 74.	1.7	21
24	Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. <i>Nature Medicine</i> , 2020, 26, 1852-1858.	15.2	104
25	Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <i>HOXA9</i> and <i>MEIS1</i> Expression. <i>Clinical Cancer Research</i> , 2020, 26, 5852-5859.	3.2	28
26	Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1965-1973.	0.6	10
27	Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. <i>Leukemia Research</i> , 2020, 95, 106402.	0.4	13
28	Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1188-1194.	0.6	7
29	Overcoming Wnt β -catenin dependent anticancer therapy resistance in leukaemia stem cells. <i>Nature Cell Biology</i> , 2020, 22, 689-700.	4.6	89
30	A Phase 1b Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6132-6140.	3.2	45
31	Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 55-56.	0.6	2
32	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML. <i>Blood</i> , 2020, 136, 44-45.	0.6	5
33	A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results. <i>Blood</i> , 2020, 136, 16-17.	0.6	19
34	First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2020, 136, 36-36.	0.6	12
35	Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 11-12.	0.6	8
36	Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. <i>Journal of Clinical Oncology</i> , 2020, 38, 7510-7510.	0.8	16

#	ARTICLE	IF	CITATIONS
37	A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.. Journal of Clinical Oncology, 2020, 38, TPS7561-TPS7561.	0.8	2
38	Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).. Journal of Clinical Oncology, 2020, 38, TPS7567-TPS7567.	0.8	2
39	Outcomes in older patients with high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 but did not undergo transplant: Phase 3 exploratory analysis.. Journal of Clinical Oncology, 2020, 38, 7537-7537.	0.8	0
40	V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia. Blood, 2020, 136, 26-28.	0.6	0
41	Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1713-1719.	2.0	7
42	A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemotherapy and Pharmacology, 2019, 84, 163-173.	1.1	10
43	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology, 2019, 37, 1277-1284.	0.8	494
44	Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. Hematology/Oncology and Stem Cell Therapy, 2019, 12, 171-173.	0.6	7
45	Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment. Annals of Hematology, 2019, 98, 481-489.	0.8	7
46	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. British Journal of Haematology, 2019, 185, 595-598.	1.2	19
47	Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood, 2019, 134, 15-15.	0.6	27
48	Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission. Blood, 2019, 134, 1316-1316.	0.6	3
49	Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).. Journal of Clinical Oncology, 2019, 37, 7042-7042.	0.8	1
50	A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies.. Journal of Clinical Oncology, 2019, 37, TPS3165-TPS3165.	0.8	3
51	The prognosis of NF1 mutations in newly diagnosed AML: A single-center retrospective study.. Journal of Clinical Oncology, 2019, 37, e18525-e18525.	0.8	0
52	Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells. Blood, 2019, 134, 2865-2865.	0.6	0
53	Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. Acta Haematologica, 2018, 139, 52-57.	0.7	0
54	Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. Hematology/Oncology and Stem Cell Therapy, 2018, 11, 135-141.	0.6	1

#	ARTICLE	IF	CITATIONS
55	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2684-2692.	0.8	682
56	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
57	Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of <i>Clostridium difficile</i> infections in allogeneic stem cell transplant. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 233-240.	0.6	12
58	A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics. <i>Leukemia Research</i> , 2018, 72, 105-112.	0.4	15
59	Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 3979-3979.	0.6	2
60	Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 564-564.	0.6	41
61	The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML. <i>Blood</i> , 2018, 132, 2706-2706.	0.6	1
62	PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. <i>Blood</i> , 2018, 132, 466-466.	0.6	24
63	Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML). <i>Journal of Clinical Oncology</i> , 2018, 36, 7040-7040.	0.8	0
64	Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML). <i>Blood</i> , 2018, 132, 1434-1434.	0.6	0
65	Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1641-1645.	2.0	14
66	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. <i>Blood</i> , 2017, 130, 890-890.	0.6	41
67	Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2016, 31, 347-352.	0.7	22
68	A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant. <i>Journal of Clinical Apheresis</i> , 2016, 31, 559-563.	0.7	6
69	Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation. <i>Blood</i> , 2016, 128, 3000-3010.	0.6	32
70	Evaluation of cytomegalovirus reactivation and tolerability in seropositive umbilical cord transplant patients after implementation of an intensive prevention strategy. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 105-111.	0.6	1
71	Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1268-1270.	1.3	68
72	Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 228-234.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.. Journal of Clinical Oncology, 2016, 34, 7000-7000.	0.8	130
74	Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.. Journal of Clinical Oncology, 2016, 34, 7007-7007.	0.8	22
75	A pilot study using hyperbaric oxygen therapy to improve umbilical cord blood stem cell engraftment: 6-months follow up results.. Journal of Clinical Oncology, 2016, 34, 7048-7048.	0.8	0
76	Transfusion support and post-transplant complications in autologous transplant patients receiving hyperbaric oxygen.. Journal of Clinical Oncology, 2016, 34, e19004-e19004.	0.8	0
77	Effect of hyperbaric oxygen treatment on chemotherapy sensitivity in acute myeloid leukemia.. Journal of Clinical Oncology, 2016, 34, e18518-e18518.	0.8	0
78	High-Risk Microgranular Acute Promyelocytic Leukemia with a Five-Way Complex Translocation Involving PML-RARA. Case Reports in Hematology, 2015, 2015, 1-3.	0.3	1
79	Rates of complete diagnostic testing for patients with acute myeloid leukemia. Cancer Medicine, 2015, 4, 519-522.	1.3	7
80	Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight. Cancer Chemotherapy and Pharmacology, 2015, 76, 691-697.	1.1	6
81	Impact of Erythropoietin Modulation Using Hyperbaric Oxygen on Umbilical Cord Blood CD34+ Cell Homing. Blood, 2015, 126, 1870-1870.	0.6	1
82	CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia. Blood, 2015, 126, 2510-2510.	0.6	7
83	Blinatumomab for Relapsed/Refractory Acute Lymphocytic Leukemia: A Single Center Experience. Blood, 2015, 126, 4912-4912.	0.6	2
84	N-Cadherin Immunoexpression in Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 4944-4944.	0.6	1
85	A Novel 3D Extracellular Matrix Model Enriching Human Acute Myeloid Leukemia Stem Cells. Blood, 2015, 126, 4959-4959.	0.6	1
86	Final Results of the First-in-Human Clinical Study Incorporating Hyperbaric Oxygen into Umbilical Cord Blood Transplantation. Blood, 2015, 126, 1909-1909.	0.6	0
87	Impact of Hyperbaric Oxygen Treatment on Time to Transfusion Independency Post-UCB Transplant. Blood, 2015, 126, 4333-4333.	0.6	0
88	Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism. Case Reports in Hematology, 2014, 2014, 1-5.	0.3	1
89	IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome. Blood Coagulation and Fibrinolysis, 2014, 25, 631-633.	0.5	8
90	Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation. Annals of Hematology, 2014, 93, 847-854.	0.8	19

#	ARTICLE	IF	CITATIONS
91	Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34+ cells in a murine model of umbilical cord blood transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 52, 59-67.	0.6	19
92	A novel three-dimensional stromal-based model for <i>in vitro</i> chemotherapy sensitivity testing of leukemia cells. <i>Leukemia and Lymphoma</i> , 2014, 55, 378-391.	0.6	89
93	Pilot Clinical Study Incorporating Hyperbaric Oxygen into Umbilical Cord Blood Transplantation. <i>Blood</i> , 2014, 124, 3889-3889.	0.6	0
94	Correlation Between Markers of Bone Turnover and Vitamin D Levels in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS). <i>Blood</i> , 2014, 124, 3471-3471.	0.6	0
95	Resistance To Chemotherapy In Leukemia Cells Grown On An Extracellular Matrix-Based Leukemia Model Derived From Wharton's Jelly. <i>Blood</i> , 2013, 122, 1388-1388.	0.6	2
96	Outpatient Cytarabine Administration Is Safe and Effective For Consolidation In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 5030-5030.	0.6	6
97	Efficacy and Relative Costs Of Re-Induction Chemotherapy With Clofarabine and Cytarabine For Adults With AML. <i>Blood</i> , 2013, 122, 5043-5043.	0.6	2
98	N-Cadherin Immunoexpression In Patients With Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 4976-4976.	0.6	0
99	Acute Myeloid Leukemia: Focus on novel Therapeutic Strategies. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7244.	0.6	31
100	Research Highlights: Highlights from the latest articles in molecular profiling and prognosis in acute myeloid leukemia. <i>Personalized Medicine</i> , 2012, 9, 679-682.	0.8	0
101	Umbilical cord graft-versus-leukemia effect induces remission without the price of graft-versus-host disease: the possible role of NK cells. <i>Clinical Transplantation</i> , 2012, 26, 663-664.	0.8	1
102	Hedgehog pathway as a drug target: Smoothed inhibitors in development. <i>OncoTargets and Therapy</i> , 2012, 5, 47.	1.0	126
103	A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumorigenic potential. <i>British Journal of Haematology</i> , 2012, 158, 79-90.	1.2	50
104	Propylene Glycol-Free Melphalan Induces Higher Remission Rates in Multiple Myeloma Patients Undergoing Autologous Transplantation. <i>Blood</i> , 2012, 120, 4551-4551.	0.6	0
105	Hyperbaric Oxygen Therapy Improves Post-Transplant Umbilical Cord Blood Engraftment. <i>Blood</i> , 2012, 120, 4663-4663.	0.6	0
106	Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. <i>Leukemia and Lymphoma</i> , 2011, 52, 1544-1555.	0.6	43
107	Prognostically Important Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia. <i>American Journal of the Medical Sciences</i> , 2011, 341, 404-408.	0.4	9
108	Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926. <i>PLoS ONE</i> , 2010, 5, e15262.	1.1	75

#	ARTICLE	IF	CITATIONS
109	The aggresome pathway as a target for therapy in hematologic malignancies. <i>Molecular Genetics and Metabolism</i> , 2008, 94, 283-286.	0.5	63
110	Role of the Aggresome Pathway in Cancer: Targeting Histone Deacetylase 6-Dependent Protein Degradation. <i>Cancer Research</i> , 2008, 68, 2557-2560.	0.4	155
111	Tubacin, An Inhibitor of HDAC6, Induces Apoptosis of Acute Lymphoblastic Leukemia Cells in Vitro and in Vivo through a Na ⁺ /K ⁺ ATPase-Dependent Pathway.. <i>Blood</i> , 2008, 112, 1923-1923.	0.6	18
112	Cancer Stem Cells: The Root of the Problem. <i>Pediatric Research</i> , 2007, 62, 239-239.	1.1	4
113	Adjuvant therapy for resected non-small-cell lung cancer: Recent advances, emerging agents, and lingering questions. <i>Current Oncology Reports</i> , 2004, 6, 251-258.	1.8	0